Table 1.
Baseline characteristics of DMARD and anti-TNF cohorts
| Characteristic | DMARD (n = 3598) | All TNF (n = 11 798) | P-value | ETN (n = 4129) | INF (n = 3467) | ADA (n = 4202) |
|---|---|---|---|---|---|---|
| Age, mean (s.d.), years | 60 (12) | 56 (12) | <0.001 | 56 (12) | 56 (12) | 57 (12) |
| Age, n (%), years | ||||||
| <55 | 1146 (32) | 5206 (44) | <0.001 | 1841 (45) | 1552 (45) | 1813 (43) |
| 55–64 | 1162 (32) | 3825 (32) | <0.001 | 1348 (33) | 1120 (32) | 1357 (32) |
| 65–74 | 926 (26) | 2280 (19) | <0.001 | 777 (19) | 635 (18) | 868 (21) |
| ≥75 | 364 (10) | 487 (4) | <0.001 | 163 (4) | 160 (5) | 164 (4) |
| Gender, female (%) | 2982 (72) | 8777 (76) | <0.001 | 3182 (77) | 2620 (76) | 3149 (76) |
| Current smoker, n (%) | 847 (24) | 2566 (22) | 0.002 | 843 (21) | 757 (22) | 966 (23) |
| Ex-smoker, n (%) | 1425 (40) | 4486 (38) | 0.002 | 1574 (38) | 1310 (38) | 1602 (38) |
| Never smoker, n (%) | 1308 (37) | 4670 (40) | 0.002 | 1686 (41) | 1382 (40) | 1602 (38) |
| Diabetes, n (%) | 234 (6.7) | 675 (5.8) | 0.045 | 254 (6.2) | 169 (4.9) | 252 (6.1) |
| COPD, n (%) | 300 (8) | 565 (5) | <0.001 | 222 (5) | 165 (5) | 178 (4) |
| Disease duration, median (IQR), years | 6 (1–15) | 11 (6–19) | <0.001 | 12 (6–19) | 12 (6–19) | 10 (5–18) |
| Baseline steroid use, n (%) | 778 (23) | 5127 (44) | <0.001 | 1972 (48) | 1607 (46) | 1613 (39) |
| DAS-28, mean (s.d.) | 5.1 (1.3) | 6.6 (1.0) | <0.001 | 6.6 (1.0) | 6.6 (1.0) | 6.5 (1.0) |
| HAQ score, mean (s.d.) | 1.5 (0.8) | 2.0 (0.6) | <0.001 | 2.1 (0.6) | 2.1 (0.5) | 1.9 (0.6) |